AnaptysBio Q3 net loss $37.3M ($1.41/sh); imsidolimab Phase 3 GPP hits primary endpoint

ANAPTYSBIO, INC

2023-Q3 EPS reported -$4.49 revenue$8,152,000

Net loss $37.3M ($1.41/sh) vs $33.5M ($1.18/sh) YoY; R&D spend rose to $30.9M.
Cash $453.3M at Sep 30, down $130.9M; reaffirms cash runway through year-end 2026.
Imsidolimab Phase 3 GPP: 53.3% achieved GPPPGA 0/1 vs 13.3% placebo (p=0.0131); out-license planned in 2024.
Initiated Phase 2b rosnilimab RA trial (420 pts); Phase 2 UC trial starting Q4 2023; top-line mid-2025 and H1 2026.
Collaboration revenue from Jemperli royalties $3.3M (vs $1.3M) helped offset net loss expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.